• search
Country
CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Antibody Drug Conjugate

Antibody Drug Conjugate

Aurigene Pharmaceutical Services provides unique advantage of having a linker-payload chemistry, antibody discovery and engineering, conjugation and characterization services under one roof. Our team has experience in working with versatile novel and standard ADC technology platforms.

Antibody, linker-payload, conjugation and analytics – we provide a one-stop solution for ADC discovery and development.

We understand the dynamic nature of the current ADC technology landscape and the complexities associated with it. Our team is well versed with a wide range of ADC technologies and is capable of adapting new technologies to support our client needs. We also provide expertise to develop novel liker technologies and cytotoxic payload optimization.

We offer a wide range of ADC services, and our team is competent at adapting new technologies to meet client requirements.

Speak to our experts

Linker Technologies

We offer services for designing and synthesizing ADC linkers and linker-drug conjugates. Based on the drug release mechanism, we design & synthesize different ADC linkers: Cleavable and non-cleavable linkers, self-immolation tracer-free linkers, and peptide linkers.

Conjugation Technologies

Our team carries out ADC conjugation services to accelerate the production of ADC constructs with quality attributes.
Amine (Lys) conjugation, thiol (Cys) conjugation, site-specific conjugation, enzymatic conjugation, glycoconjugation and click chemistry.

Payloads

According to clients’ requirements, we optimize payloads such as cytotoxic, non-cytotoxic, and biological payloads. Our team handles a wide range of cytotoxic payloads, including:

  • Auristatins (MMAE and MMAF)
  • Tubulysin
  • PBD Dimer
  • Maytansinoids (DM-1, DMO4)
  • Duocarmycin
  • Exatecans

ADC Discovery (Therapeutics and Tools or Reagents) and Development

Our ADC discovery programs are customized as per the target biology and desired mechanism of action. Specific screening strategies are designed and employed at a stage as early as antibody generation. Some of the early stage activities include screening and design of mAbs for internalization (or lack of it), effector function, off-site localization and half-life.

Rapid and comprehensive scouting of the linker-payload technology space can be plugged-in to identify the most desirable combinations of mAb, linker-payload and conjugation strategies. Stage appropriate in vitro screening and detailed evaluation of lead ADC molecules is carried out using customized assay platforms.

We also provide in vivo therapeutic evaluation, PK, and rodent toxicology assessment support for ADC candidates with appropriate bioanalytical methods customized for each program. Conjugation and purification process development takes into account each component of the ADC molecule. Quality, scalability, safety and cost-effectiveness concerns are addressed at each stage of process development.

ADC Analysis

A biomolecule is complex as an ADC and demands analytical assessment to ensure safety and quality. Routinely determined attributes during ADC analysis are

  • DAR average
  • Free-drug
  • Conjugation site
  • Aggregation
  • Fragmentation
  • Endotoxin
  • Antigen binding affinity
  • Plasma stability
  • In vitro potency

Why Aurigene Pharmaceutical Services?

Site-specific conjugation technology

In-house linker library and Payload

Collaborative and solution driven

Analytical assessment to ensure safety and quality

Various commercial and customized linkers

Virtual Tour

 

Contact Us

Country
CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
resourceMainImage

JUNE 28, 2022

Neoantigen Specific T cells For Cancer Immunotherapy

Neoantigen specific T cells for cellular cancer immunotherapy An effective anti-tumor immune response in human is marked by presence of T cells reactive against neoantigens. Neoantigens are HLA-bound unique peptides arise from tumor-specific somatic mutations. Neoantigens are highly immunogenic because they are not present in normal tissues and hence...

Read More
resourceMainImage

Building successful long-term partnerships with CDMOs from early drug discovery through commercialization

Building successful long-term partnerships with CDMOs from early drug discovery through commercialization Maximizing efficiency in drug research, development, and manufacturing is crucial for turning new innovations into therapeutic and financial benefits. Over the past couple of decades, pharmaceutical companies have increasingly turned to contr...

Read More
resourceMainImage

Technology meets sustainability - How a complex API development process goes green

We are always looking for ways to enhance the sustainability of our products and services. Our team successfully developed a scalable manufacturing process for the API product of one of our Biotech clients using eco-friendly manufacturing technologies. Read the case study to learn more. ...

Read More

Alternate end-game strategies towards Nirmatrelvir synthesis: Defining a continuous flow process for the preparation of an anti-COVID drug

2023

Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...

Read More
View All
×

You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.

If you wish to continue to this external website, click Proceed.

ProceedBack